Uniting our global researchers for melanoma
28 October 2016
Melanoma Institute Australia (MIA) is bringing to Sydney some of the world’s leading melanoma researchers and clinicians today for the Australasian Melanoma Conference.
More than 380 researchers, clinicians, nurses and students are attending the two-day conference held at the Sofitel Wentworth in Sydney. The conference, hosted by MIA, is bringing together some of the greatest minds in melanoma research to showcase current practice and research innovation that will make a difference to the lives of melanoma patients.
MIA’s Associate Professor Robyn Saw, Chair of the Australasian Melanoma Conference, says this year’s event is an opportunity for physicians and researchers to learn about ground-breaking research and revolutionary melanoma treatment.
“The conference is a truly unique opportunity to build strong Australasian collaboration and to acquire information and knowledge to use in every day practice,” Associate Professor Saw says.
During the conference, MIA’s Associate Professor Jonathan Stretch AM is launching the new eBook Melanoma Principles & Practice, an interactive multi-touch e-textbook on melanoma care and treatment aimed at specialists.
Written and designed by MIA, the eBook is set to become an ultimate resource on melanoma, delivering specialists a seamless experience that supplements the text with interactive visual supports to build a multi-dimensional level of understanding that would not be possible from a printed book.
The Conference features a number of international keynote speakers. Dr Vernon Sondak from the Moffitt Cancer Center in the US is discussing melanoma in children and how to improve diagnosis and management, as well as communication with the young patient and their family.
Associate Professor Jennifer Wargo from MD Anderson Cancer Center is discussing her research on how gut flora – known as the microbiome – play a role in determining how well a patient responds to treatment.
“There is emerging evidence regarding the role of the microbiome in response to melanoma therapy, and it is quite likely that we will modify the microbiome to enhance responses to therapy in the upcoming months and years,” says Associate Professor Wargo.
Professor John Thompson AO from MIA is reporting on the new electronic clinical practice guidelines for the diagnosis and management of melanoma.
“Things are moving quickly in melanoma management. A comprehensive systematic review of the evidence was timely," Professor Thompson says. “Extensive use of the new guidelines will help to ensure that clinicians have access to the latest evidence-based recommendations when diagnosing and caring for people with melanoma."
More than 30 speakers are presenting at the Australasian Melanoma Conference, including a contingent of MIA experts such as Professor Richard Scolyer and Professor Georgina Long, as well as other eminent Australians in the field such as Professor Grant McArthur and Dr Mark Shackleton from the Peter MacCallum Cancer Centre.
Delegates are sharing insights and key learnings on social media throughout the day using the hashtag #MelanomaConf2016.
The Australasian Melanoma Conference is proudly sponsored by Bristol-Myers Squibb, MSD, Novartis, Sonic Healthcare, Amgen, Laverty Pathology and Pierre Fabre Australia.
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.
We value your privacy and want you to be familiar with how we collect, use and disclose your information.
Melanoma Institute Australia has partnered with IBM Research in Australia to help further advance melanoma identification using cognitive technology.
CEO Carole Renouf chats to senior clinicians and researchers as part of our "4 Questions With..." short video series.
MIA's 'Stop the Spread' campaign has been shortlisted in the 2016 Cannes Lions International Festival of Creativity.